profit from every $100 of sales.
$0$100
Nexgel
$0.01-12.86% today
-98.2% in 1 year
1-year low $0.011-year high $0.34
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Nexgel sold, what it kept, and what it did with the cash.
Sales went from $2.05 million in 2022 to $11.4 million in 2025, with -$3.00 million of profit last year.
SalesProfit
Nexgel vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nexgel | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Nexgel's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2 | 4 | 9 | 11 | |
| 0 | 0 | 3 | 5 | |
| -3 | -3 | -4 | -3 | |
| -3 | -3 | -3 | -2 | |
| -5 | -3 | -3 | -3 | |
| – | – | – | – | |
| 12.5% | 9.1% | 31.6% | 39.5% | |
| -163.5% | -85.0% | -40.9% | -29.3% | |
| -231.7% | -77.2% | -37.8% | -26.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 10 | 10 | 11 | 10 |
| Cash | 1 | 3 | 2 | 0 |
| Total debt | 2 | 3 | 3 | 3 |
| Total liabilities | 3 | 5 | 5 | 6 |
| 8 | 5 | 6 | 4 | |
| – | – | – | – | |
| -27.7% | -33.4% | -31.1% | -29.9% | |
| -62.1% | -67.2% | -57.0% | -67.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -3 | -3 | -4 | -1 | |
| 0 | 1 | 0 | 0 | |
| -3 | -4 | -4 | -1 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 0 | 0 | 1 |
Valuation
- –
- 0.0×
- –
- 1.1×
- 0.4×
- –
- –
- -31.8%
- -72.6%
- 0.0%
Profitability
- 39.5%
- -29.3%
- -26.3%
- -25.8%
- -40.8%
- -39.1%
- -70.2%
- -27.7%
- -42.6%
- 0.1%
Growth
- +77.3%
- –
- +68.0%
- –
- +9.0%
Financial health
- –
- 1.05
- 36.1%
- 185.9×
- 1.70
- 1.02
- 0.97
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 952
Bottom 9%of 884
Top 7%of 886
Bottom 2%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.11 | -0.07 | −57.1% |
| Mar 31, 2026 | -0.12 | -0.09 | −33.3% |
| Nov 11, 2025 | -0.08 | -0.08 | −2.4% |
| Aug 12, 2025 | -0.09 | -0.07 | −24.1% |
| May 13, 2025 | -0.09 | -0.10 | +6.9% |
| Sep 30, 2023 | -0.00 | – | – |
| Jun 30, 2023 | -0.00 | – | – |
| Mar 31, 2023 | -0.00 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
48No pass
Philip Fisher
34No pass
Peter Lynch
61Pass
Joel Greenblatt
0No pass
Charlie Munger
14No pass
Terry Smith
22No pass
Questions about Nexgel
Is Nexgel a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nexgel AI analysis
What does Nexgel do?
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It is in Medical - Instruments & Supplies.
Does Nexgel pay a dividend?
No. Nexgel does not pay a dividend at the moment.
How has Nexgel stock done over the past year?
Down 98.2% over the past twelve months, to $0.01. It traded between $0.01 and $0.34 and is 98.2% below its high.
Who are Nexgel's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Nexgel's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.